Epidermal growth factor receptor determination on tumour imprints.
AUTOR(ES)
Hastrich, D J
RESUMO
Epidermal growth factor receptor (EGFR) is a sensitive prognostic indicator in women with breast cancer. A new technique for the detection of EGFR on breast cancer imprints is described and evaluated in relation to immunohistochemistry on frozen sections. The standard streptavidin-biotin method using the R1 antibody on frozen sections was modified for use on tumour imprints. In the first group (group 1 imprints) 43 tumours were assessed by frozen section and imprint staining. The group 1 imprint method had a sensitivity of 50% and a specificity of 89% compared with the frozen sections. Further modifications were made for the following 32 tumours (group 2) and this method had a much improved sensitivity of 94% while specificity was preserved. This method is simple and could be performed in any hospital histopathology department.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=501150Documentos Relacionados
- A transcription factor active on the epidermal growth factor receptor gene.
- Human epidermal growth factor receptor residue covalently cross-linked to epidermal growth factor.
- Epidermal growth factor receptor regulates pancreatic fibrosis
- Platelet-derived growth factor mimics phorbol diester action on epidermal growth factor receptor phosphorylation at threonine-654.
- Modulation of the epidermal growth factor receptor by platelet-derived growth factor and choleragen: Effects on mitogenesis
